Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma | Zendy

Laurence Albigès | Zendy; Stéphane Oudard | Zendy; Sylvie Négrier | Zendy; Armelle Caty | Zendy; Gwénaëlle Gravis | Zendy; Florence Joly | Zendy; Brigitte Duclos | Zendy; L. Geoffrois | Zendy; Frédéric Rolland | Zendy; Aline Guillot | Zendy; Brigitte Laguerre | Zendy; Éric Legouffe | Zendy; F. Kohser | Zendy; PierreYves Dietrich | Zendy; C Théodore | Zendy; Bernard Escudier | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma

Author(s) -

Laurence Albigès,

Stéphane Oudard,

Sylvie Négrier,

Armelle Caty,

Gwénaëlle Gravis,

Florence Joly,

Brigitte Duclos,

L. Geoffrois,

Frédéric Rolland,

Aline Guillot,

Brigitte Laguerre,

Éric Legouffe,

F. Kohser,

PierreYves Dietrich,

C Théodore,

Bernard Escudier

Publication year - 2012

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2011.37.2516

Subject(s) - medicine , sunitinib , sorafenib , renal cell carcinoma , tyrosine kinase inhibitor , surgery , gastroenterology , cancer , hepatocellular carcinoma

Complete remission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may occur in some patients. It remains a matter of debate whether therapy should be continued after CR.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research